Keiichiro Mori

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5337869/publications.pdf

Version: 2024-02-01

		361413	477307
148	1,811	20	29
papers	citations	h-index	g-index

150	150	150	1616
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 755-765.	5.4	100
2	Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. European Urology, 2021, 80, 549-563.	1.9	53
3	The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. European Urology, 2021, 79, 783-792.	1.9	46
4	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1892-1900.	2.2	45
5	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunology, Immunotherapy, 2021, 70, 265-273.	4.2	44
6	A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. Journal of Urology, 2020, 204, 1129-1140.	0.4	41
7	En bloc resection for nonmuscle invasive bladder cancer. Current Opinion in Urology, 2020, 30, 41-47.	1.8	40
8	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Nonâ€“muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 927-942.	5.4	40
9	Systemic therapies for metastatic hormoneâ€sensitive prostate cancer: network metaâ€analysis. BJU International, 2022, 129, 423-433.	2.5	37
10	The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 205, 60-67.	0.4	36
11	Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 315-333.	1.6	32
12	Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1037-1054.	2.2	31
13	Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 1075-1084.	0.4	30
14	Lactate dehydrogenase predicts combined progressionâ€free survival after sequential therapy with abiraterone and enzalutamide for patients with castrationâ€resistant prostate cancer. Prostate, 2017, 77, 1144-1150.	2.3	29
15	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2020, 23, 539-548.	3.9	27
16	Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials. Journal of Urology, 2021, 205, 1018-1030.	0.4	27
17	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 774-782.	1.6	26
18	Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 247-257.	2.2	25

#	Article	IF	Citations
19	Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1459-1474.	2.2	25
20	Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and metaâ€analyses. BJU International, 2021, 128, 3-11.	2.5	25
21	Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2019, 17, 409-418.	1.9	24
22	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. European Journal of Cancer, 2021, 151, 35-48.	2.8	24
23	The Prognostic Association of Prostate MRI PI-RADSâ„¢ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 206, 507-516.	0.4	22
24	Prognostic role of the systemic immuneâ€“inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. Cancer Immunology, Immunotherapy, 2021, 70, 2641-2650.	4.2	21
25	The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 204, 909-917.	0.4	21
26	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. World Journal of Urology, 2021, 39, 1757-1768.	2.2	20
27	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 95.e1-95.e6.	1.9	20
28	Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. World Journal of Urology, 2022, 40, 907-914.	2.2	19
29	Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 204, 58-62.	0.4	19
30	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2022, 27, 59-71.	2.2	19
31	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 3345-3352.	2.2	18
32	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. World Journal of Urology, 2021, 39, 4355-4361.	2.2	18
33	Smoking and bladder cancer: review of the recent literature. Current Opinion in Urology, 2020, 30, 720-725.	1.8	17
34	Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of nonâ€muscleâ€invasive bladder cancer: a systematic review and network metaâ€analysis of randomized trials. BJU International, 2021, 128, 280-289.	2.5	17
35	Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 409-421.	1.6	17
36	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU International, 2022, 129, 182-193.	2.5	16

#	Article	IF	Citations
37	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2021, 26, 1587-1599.	2.2	16
38	Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. Current Oncology, 2021, 28, 2881-2892.	2.2	16
39	The Impact of Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma: A Comprehensive Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4197.	2.4	16
40	Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2020, 18, e402-e409.	1.9	15
41	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2022, 82, 82-96.	1.9	15
42	Catalog of exogenous risk factors for bladder carcinogenesis. Current Opinion in Urology, 2020, 30, 449-456.	1.8	14
43	Impact of systemic Immuneâ€“inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 785.e19-785.e27.	1.6	14
44	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 764-773.	1.6	14
45	Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. European Urology Focus, 2022, 8, 1072-1089.	3.1	14
46	Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 106.e11-106.e19.	1.6	14
47	Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axisâ€“Targeted Agents. Clinical Genitourinary Cancer, 2019, 17, 223-230.	1.9	13
48	Value of tumourâ€infiltrating immune cells in predicting response to intravesical BCG in patients with nonâ€muscleâ€invasive bladder cancer: a systematic review and metaâ€analysis. BJU International, 2021, 127, 617-625.	2.5	13
49	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 99, 102242.	7.7	13
50	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. International Immunopharmacology, 2022, 108, 108720.	3.8	13
51	Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 601.e17-601.e24.	1.6	12
52	Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. Arab Journal of Urology Arab Association of Urology, 2021, 19, 59-66.	1.5	12
53	Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 239-252.	3.1	12
54	Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. European Urology Focus, 2022, 8, 710-717.	3.1	12

#	Article	IF	Citations
55	Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2020, 18, e517-e522.	1.9	11
56	Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2. Current Opinion in Urology, 2021, 31, 304-314.	1.8	11
57	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. Journal of Endourology, 2022, 36, 535-547.	2.1	11
58	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Critical Reviews in Oncology/Hematology, 2022, 169, 103570.	4.4	11
59	Volume outcome relationship in penile cancer: a systematic review. Current Opinion in Urology, 2020, 30, 696-700.	1.8	10
60	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). World Journal of Urology, 2020, 39, 1961-1968.	2.2	10
61	Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 180-190.	1.6	10
62	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. European Urology Focus, 2022, 8, 761-768.	3.1	10
63	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. World Journal of Urology, 2021, 39, 3771-3779.	2.2	10
64	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 1687-1695.	3.1	10
65	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2022, 14, 709-725.	2.0	10
66	Earlier use of androgen receptorâ€axisâ€targeted drugs may improve overall survival in patients with nonâ€metastatic castrationâ€resistant prostate cancer. Prostate, 2018, 78, 766-772.	2.3	9
67	Shortâ€term impact of androgen deprivation therapy on bone strength in castrationâ€sensitive prostate cancer. International Journal of Urology, 2019, 26, 980-984.	1.0	9
68	Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up. Clinical Genitourinary Cancer, 2020, 18, e46-e54.	1.9	9
69	Primary Ta high grade bladder tumors: Determination of the risk of progression. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 132.e7-132.e11.	1.6	9
70	Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. Current Opinion in Urology, 2021, 31, 332-339.	1.8	9
71	Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. World Journal of Urology, 2021, 39, 4085-4099.	2.2	9
72	Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for highâ€risk metastatic hormoneâ€sensitive prostate cancer. Prostate, 2022, 82, 3-12.	2.3	9

#	Article	IF	Citations
73	Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 531-542.	3.9	9
74	Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1881-1891.	2.2	8
75	The clinical pharmacology of the medical treatment for overactive bladder in adults. Expert Review of Clinical Pharmacology, 2020, 13, 707-720.	3.1	8
76	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	1.6	8
77	Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1. Current Opinion in Urology, 2021, 31, 297-303.	1.8	8
78	Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. European Urology Focus, 2022, 8, 752-760.	3.1	8
79	Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers. World Journal of Urology, 2022, 40, 1317-1323.	2.2	8
80	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva Urology and Nephrology, 2022, 74, .	2.5	8
81	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urology and Nephrology, 2021, , .	2.5	8
82	The significance of De Ritis ratio in patients with radiation-recurrent prostate cancer undergoing salvage radical prostatectomy. Arab Journal of Urology Arab Association of Urology, 2020, 18, 213-218.	1.5	7
83	Management of de-novo urothelial carcinoma in transplanted patients. Current Opinion in Urology, 2020, 30, 467-474.	1.8	7
84	What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. Current Opinion in Urology, 2021, 31, 276-284.	1.8	7
85	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. European Journal of Surgical Oncology, 2021, 47, 1172-1178.	1.0	7
86	Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 806-815.	1.6	7
87	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 471-479.	1.6	7
88	Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Current Opinion in Urology, 2022, 32, 61-68.	1.8	7
89	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urologyâ€"Young Academic Urologists: Urothelial Carcinoma Working Group. European Urology Focus, 2022, 8, 1635-1642.	3.1	7
90	Comparative Outcomes of Primary Versus Recurrent High-risk Nonâ€"muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. European Urology Open Science, 2022, 39, 14-21.	0.4	7

#	Article	IF	Citations
91	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. Current Opinion in Urology, 2020, Publish Ahead of Print, 701-710.	1.8	6
92	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2020, 39, 2567-2577.	2.2	6
93	Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. European Urology Focus, 2021, 7, 1143-1156.	3.1	6
94	Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. World Journal of Urology, 2021, 39, 2977-2985.	2.2	6
95	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	4.2	6
96	The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. European Urology Oncology, 2022, 5, 138-145.	5.4	6
97	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Molecular Carcinogenesis, 2022, 61, 5-18.	2.7	6
98	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. Minerva Urology and Nephrology, 2021, 73, 610-615.	2.5	6
99	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. European Urology Oncology, 2022, 5, 120-124.	5.4	6
100	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Annals of Surgical Oncology, 2022, 29, 5307-5316.	1.5	6
101	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. Journal of Robotic Surgery, 2022, 16, 1233-1247.	1.8	6
102	The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and metaâ€analysis. BJU International, 2021, 127, 143-152.	2.5	5
103	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. OncoTargets and Therapy, 2021, Volume 14, 315-324.	2.0	5
104	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Translational Andrology and Urology, 2021, 10, 609-619.	1.4	5
105	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. Journal of Urology, 2021, 206, 1122-1131.	0.4	5
106	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. Journal of Personalized Medicine, 2021, 11, 1231.	2.5	5
107	The placebo and nocebo effects in functional urology. Nature Reviews Urology, 2022, 19, 171-189.	3.8	5
108	Bladder-preserving strategies for Bacillus Calmette-GuÃ©rin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?. Current Opinion in Urology, 2020, 30, 584-593.	1.8	5

#	Article	IF	Citations
109	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2021, 51, 1149-1157.	1.3	4
110	A systematic review and meta-analysis of prognostic impact of different Gleason patterns in ISUP grade group 4. Minerva Urology and Nephrology, 2021, 73, 42-49.	2.5	4
111	Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 976-985.	2.0	4
112	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. Prostate, 2021, 81, 765-771.	2.3	4
113	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. World Journal of Urology, 2022, 40, 747-754.	2.2	4
114	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 936.e7-936.e14.	1.6	3
115	Intravesical Therapy in Patients with Intermediate-risk Nonâ€“muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. European Urology Focus, 2022, 8, 447-456.	3.1	3
116	Association between male infertility and prostate cancer: a systematic review and meta-analysis. Current Opinion in Urology, 2021, 31, 346-353.	1.8	3
117	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. Annals of Surgical Oncology, 2021, 28, 9179-9187.	1.5	3
118	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 1729-1735.	2.2	3
119	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. World Journal of Urology, 2021, , 1.	2.2	3
120	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. Clinical Genitourinary Cancer, 2022, 20, 227-236.	1.9	3
121	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. European Urology Focus, 2022, 8, 972-979.	3.1	3
122	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. Scandinavian Journal of Urology, 2022, 56, 85-93.	1.0	3
123	Prognostic impact of insulinâ€like growth factorâ€I and its binding proteins, insulinâ€like growth factorâ€I binding proteinâ€2 and â€3, on adverse histopathological features and survival outcomes after radical cystectomy. International Journal of Urology, 2022, , .	1.0	3
124	Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis. World Journal of Urology, 0, , .	2.2	3
125	Presence of biopsy Gleason pattern 5â€‰+â€‰3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+. Prostate, 2021, 81, 778-784.	2.3	2
126	Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 205, 1559-1568.	0.4	2

#	Article	IF	Citations
127	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. Minerva Urology and Nephrology, 2022, 74, .	2.5	2
128	Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. Seminars in Oncology, 2021, 48, 181-192.	2.2	2
129	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 685.e17-685.e25.	1.6	2
130	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. Central European Journal of Urology, 2021, 74, 484-490.	0.3	2
131	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	2.5	2
132	Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. Arab Journal of Urology Arab Association of Urology, 2022, 20, 71-80.	1.5	2
133	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. Translational Cancer Research, 2022, 11, 908-917.	1.0	2
134	No survival benefit found after extended treatment with docetaxel for patients with castrationâ€resistant prostate cancer. Prostate, 2019, 79, 1604-1610.	2.3	1
135	Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2020, 25, 479-485.	2.2	1
136	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. Turkish Journal of Urology, 2021, 47, S33-S44.	1.3	1
137	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. Immunotherapy, 2021, 13, 917-929.	2.0	1
138	The Impact of Primary Tumor Location on Long-Term Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 2021, 11, 1363.	2.5	1
139	Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. European Urology, 2020, 77, 758-759.	1.9	0
140	Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 79, 430-431.	1.9	0
141	Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasserâ€™s Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?. European Urology, 2021, 79, e113-e114.	1.9	0
142	ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?. Annals of Surgical Oncology, 2021, 28, 9188-9189.	1.5	0
143	Reply to Xiaoshuai Gao, Guo Chen, and Xin Weiâ€™s Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783â€“92. European Urology, 2021, 80, e145-e146.	1.9	0
144	Does Gleason pattern 5 influence the efficacy of enzalutamide against castration-resistant prostate cancer?. Journal of Clinical Oncology, 2017, 35, e598-e598.	1.6	0

#	Article	IF	Citations
145	The association of PSA levels and survival outcomes in patients with chemotherapy-naÃ¯ve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.. Journal of Clinical Oncology, 2019, 37, 315-315.	1.6	0
146	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	2.2	0
147	ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?. Annals of Surgical Oncology, 2022, , 1.	1.5	0
148	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. Annals of Surgical Oncology, 2022, , 1.	1.5	0